```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN
 NEWS 20  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS 21  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *
```

```
FILE 'HOME' ENTERED AT 15:44:55 ON 01 FEB 2004

=> file medline, biosis, wpids, fsta, jicst, hcaplus, embase, dgene
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY    SESSION
FULL ESTIMATED COST                             1.26       1.26

FILE 'MEDLINE' ENTERED AT 15:48:28 ON 01 FEB 2004

FILE 'BIOSIS' ENTERED AT 15:48:28 ON 01 FEB 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 15:48:28 ON 01 FEB 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 15:48:28 ON 01 FEB 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 15:48:28 ON 01 FEB 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'HCAPLUS' ENTERED AT 15:48:28 ON 01 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:48:28 ON 01 FEB 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 15:48:28 ON 01 FEB 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

=> s tonicity modifier
L1          41 TONICITY MODIFIER

=> s isotonicity
L2        1184 ISOTONICITY

=> s l1 and l2
L3           2 L1 AND L2

=> d l3 ti abs ibib tot

L3   ANSWER 1 OF 2  WPIDS  COPYRIGHT 2004 THOMSON DERWENT on STN
TI   Stable liquid formulation suitable for subcutaneous injection and for
     retaining the physical and chemical and biological stability of antibody,
     has succinate or histidine buffer, and a tonicity
     modifier.
AN   2003-505039 [47]   WPIDS
AB   WO2003039485 A UPAB: 20030723
     NOVELTY - A stable liquid formulation (I) comprising 20-60 mM succinate
     buffer or 30-70 mM histidine buffer, has pH 5.5-6.5, 0.01-0.1%
     polysorbate, and a tonicity modifier that contributes
     to isotonicity of the formulation, and greater than 50 mg/ml
     antibody, is new.
          USE - (I) is useful for subcutaneous injection, and for retaining the
     physical and chemical and biological stability of antibodies, and prevents
     the immunoglobulins intended for administration to human subjects from
     forming aggregates and particulates in the final product.
     Dwg.0/4
ACCESSION NUMBER:      2003-505039 [47]   WPIDS
DOC. NO. CPI:          C2003-134902
TITLE:                 Stable liquid formulation suitable for subcutaneous
                       injection and for retaining the physical and chemical and
```

biological stability of antibody, has succinate or histidine buffer, and a **tonicity modifier**.

DERWENT CLASS: A96 B04 D16
INVENTOR(S): DUVUR, S G; GUPTA, S; KAISHEVA, E A; SUBRAMANIAN, M
PATENT ASSIGNEE(S): (DUVU-I) DUVUR S G; (GUPT-I) GUPTA S; (KAIS-I) KAISHEVA E A; (SUBR-I) SUBRAMANIAN M; (PROT-N) PROTEIN DESIGN LABS INC
COUNTRY COUNT: 102
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003039485	A2	20030515	(200347)*	EN	36

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

US 2003138417 A1 20030724 (200352)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003039485 A2		WO 2002-US36093	20021108
US 2003138417 A1	Provisional	US 2001-337509P	20011108
		US 2002-291528	20021108

PRIORITY APPLN. INFO: US 2001-337509P 20011108; US 2002-291528 20021108

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Stable liquid pharmaceutical formulation of IgG antibodies
AB This invention is directed to a stable liq. pharmaceutical formulation comprising a high concn., e.g. 50 mg/mL or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1 % polysorbate, and a **tonicity modifier** that contributes to the **isotonicity** of the formulation. This liq. formulation is stable at refrigerated temp. (2-8.degree.C) for at least 1 yr, and preferably 2 yr. This liq. formulation is suitable for s.c. injection. This invention is exemplified by Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

ACCESSION NUMBER: 2003:376584 HCAPLUS
DOCUMENT NUMBER: 138:390914
TITLE: Stable liquid pharmaceutical formulation of IgG antibodies
INVENTOR(S): Kaisheva, Elizabet A.; Gupta, Supriya; Duvur, Shanti G.; Subramanian, Malathy
PATENT ASSIGNEE(S): Protein Design Labs, USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     ---------------  ----  --------        ---------------  --------
     WO 2003039485     A2   20030515        WO 2002-US36093  20021108
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2003138417     A1   20030724        US 2002-291528   20021108
PRIORITY APPLN. INFO.:                   US 2001-337509P  P  20011108


=> d his

     (FILE 'HOME' ENTERED AT 15:44:55 ON 01 FEB 2004)

     FILE 'MEDLINE, BIOSIS, WPIDS, FSTA, JICST-EPLUS, HCAPLUS, EMBASE, DGENE'
     ENTERED AT 15:48:28 ON 01 FEB 2004
L1            41 S TONICITY MODIFIER
L2          1184 S ISOTONICITY
L3             2 S L1 AND L2

=> s glycerin
L4         39775 GLYCERIN

=> s glycerol
L5        247256 GLYCEROL

=> s l4 and l5
L6          4368 L4 AND L5

=> s l6 and l1
L7             4 L6 AND L1

=> d l7 ti abs ibib tot

L7   ANSWER 1 OF 4     MEDLINE on STN
TI   Adsorption of esters of p-hydroxybenzoic acid by filter membranes:
     mechanism and effect of formulation and processing parameters.
AB   The adsorption of esters of p-hydroxybenzoic acid (parabens) by filter
     membranes was studied by a flow-through technique. The hydrophobic effect
     was the major mechanism of adsorption. Propylparaben was more extensively
     adsorbed by all the membranes than was methylparaben. Hydrophobic
     membranes exhibited the greatest degree of adsorption, whereas adsorption
     was minimal for hydrophilic membranes. The charge of the filter membrane
     did not affect paraben adsorption. Formulation factors studied included
     the concentration of paraben, the presence of a tonicity-modifying agent
     (sodium chloride, mannitol, glycerin), and the presence of a
     chelating agent (edetate sodium). Paraben adsorption was directly related
     to paraben concentration. The presence of a tonicity
     modifier or chelating agent did not alter paraben adsorption to
     membrane filters. Processing parameters studied included flow rate,
     temperature, autoclaving, flow interruption, and filter membrane
     presaturation. Presaturation of the filter membranes for up to 1 hr
     reduced but did not eliminate paraben adsorption during simulated use.
     Interrupting the flow of the paraben solution through the filter membrane
     allowed for additional paraben adsorption and caused the concentration of
     paraben in the restarted filtrate to be less than 100% of theory.
ACCESSION NUMBER:   2000134819     MEDLINE
```

DOCUMENT NUMBER: 20134819 PubMed ID: 10669923
TITLE: Adsorption of esters of p-hydroxybenzoic acid by filter membranes: mechanism and effect of formulation and processing parameters.
AUTHOR: Bin T; McCrosky L; Kulshreshtha A K; Hem S L
CORPORATE SOURCE: Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana 47907, USA.
SOURCE: PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, (2000) 5 (1) 95-104.
Journal code: 9610932. ISSN: 1083-7450.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200002
ENTRY DATE: Entered STN: 20000314
Last Updated on STN: 20000314
Entered Medline: 20000229

L7 ANSWER 2 OF 4 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Lamotrigine particles useful as adjunct medication in epilepsy therapy for reducing incidence of seizures have specific surface areas.
AN 2004-011713 [01] WPIDS
AB WO2003090693 A UPAB: 20040102
NOVELTY - Lamotrigine particles have specific surface areas of 2 - 3.5 (preferably 3) m2/g.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:
(1) a pharmaceutical composition comprising the several lamotrigine particles; and
(2) a dosage form (preferably oral or parenteral dosage form) comprising the composition.
ACTIVITY - Anticonvulsant.
MECHANISM OF ACTION - None given.
USE - For reducing the incidence of seizures (claimed) e.g. as an adjunct in the treatment of epilepsy.
ADVANTAGE - The lamotrigine particles exhibit improved solubility, bioavailability and dissolution rate, compared to the prior art lamotrigine particles.
Dwg.0/0
ACCESSION NUMBER: 2004-011713 [01] WPIDS
DOC. NO. CPI: C2004-003384
TITLE: Lamotrigine particles useful as adjunct medication in epilepsy therapy for reducing incidence of seizures have specific surface areas.
DERWENT CLASS: A96 B03
INVENTOR(S): ARONHIME, J; SAMBURSKI, G
PATENT ASSIGNEE(S): (TEVA-N) TEVA PHARM IND LTD; (TEVA-N) TEVA PHARM USA INC
COUNTRY COUNT: 103
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003090693	A2	20031106	(200401)*	EN	12

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003090693	A2	WO 2003-US13002	20030423

PRIORITY APPLN. INFO: US 2002-374923P 20020423

L7 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Injectable aqueous dispersions of propofol
AB Irritation upon injection of a formulation contg. propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aq. dispersion comprising a water-insol. microdroplet matrix of mean diam. from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-sol. diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic agent. The aq. phase includes a pharmaceutically acceptable water-sol. polyhydroxy **tonicity modifier**. The propofol-contg. dispersion is devoid of addnl. bactericidal or bacteriostatic preservative agents. A pharmaceutical injection contained propofol 5.0, cholesterol 0.25, phospholipon 90H 1.5, DMPG 0.3, **glycerol** 2.5, sodium hydroxide q.s. pH 6.9, and water 100%. Upon i.v. administration to rats of a dose at 10 mg/kg, the formulation demonstrated acceptable efficacy of general anesthesia.

ACCESSION NUMBER: 2002:51904 HCAPLUS
DOCUMENT NUMBER: 136:107548
TITLE: Injectable aqueous dispersions of propofol
INVENTOR(S): Mishra, Awadhesh K.; Pace, Gary W.; Vachon, Michael G.
PATENT ASSIGNEE(S): Rtp Pharma Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Division of U.S. Ser. No. 376,487.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002006442	A1	20020117	US 2001-820371	20010326
US 2003165544	A1	20030904	US 1999-376487	19990818
PRIORITY APPLN. INFO.:			US 1998-97071P P	19980819
			US 1999-376487 A3	19990818

L7 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Injectable aqueous dispersions of propofol
AB A stable, sterile, and injectable aq. dispersion of a water-insol. microdroplet matrix of mean diam. from about 50 nm to about 1000 nm consisting essentially of between about 1 % to about 15 % of propofol; between about 1 % to about 8 % of a propofol sol. diluent; between about 0.5 % to about 5 % of a surface stabilizing amphiphilic agent; of a pharmaceutically acceptable water-sol. polyhydroxy additive that acts as a **tonicity modifier**; and provided the ratio of propofol to diluent is about 1:4 to about 1:0.1 and the ratio of propofol to amphiphilic agent is about 1:0.8 to about 1:2.5, and the compn. has a viscosity of from about 0.8 to about 15 cP. A pharmaceutical injection contained propofol 5.0, cholesterol 0.25, phospholipon 90H 1.5, 1,2-dimyristoyl-sn-glycero-3-phosphocholine 0.3, **glycerol** 2.5, sodium hydroxide q.s. pH = 6.9, and water q.s. 100%. The injection was very stable and upon i.v. administration to rats of a dose at 10 mg/kg, it showed acceptable efficacy of general anesthesia.

ACCESSION NUMBER: 2000:144706 HCAPLUS
DOCUMENT NUMBER: 132:185447
TITLE: Injectable aqueous dispersions of propofol
INVENTOR(S): Mishra, Awadhesh K.; Pace, Gary W.

```
PATENT ASSIGNEE(S):      RTP Pharma Inc., USA
SOURCE:                  PCT Int. Appl., 41 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2000010531      A1   20000302       WO 1999-US18801  19990818
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2338703         AA   20000302       CA 1999-2338703  19990818
     AU 9955705         A1   20000314       AU 1999-55705    19990818
     AU 759641          B2   20030417
     EP 1105096         A1   20010613       EP 1999-942292   19990818
     EP 1105096         B1   20031029
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002523356      T2   20020730       JP 2000-565853   19990818
     AT 252889          E    20031115       AT 1999-942292   19990818
     SE 2001000254      A    20010404       SE 2001-254      20010130
PRIORITY APPLN. INFO.:                   US 1998-97071P   P  19980819
                                         WO 1999-US18801  W  19990818
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 15:44:55 ON 01 FEB 2004)

     FILE 'MEDLINE, BIOSIS, WPIDS, FSTA, JICST-EPLUS, HCAPLUS, EMBASE, DGENE'
     ENTERED AT 15:48:28 ON 01 FEB 2004
L1            41 S TONICITY MODIFIER
L2          1184 S ISOTONICITY
L3             2 S L1 AND L2
L4         39775 S GLYCERIN
L5        247256 S GLYCEROL
L6          4368 S L4 AND L5
L7             4 S L6 AND L1

=> s stable formulation solution ()GLP-1
L8             0 STABLE FORMULATION SOLUTION (W) GLP-1

=> s GLP-1 () solution
L9            38 GLP-1 (W) SOLUTION

=> d l9 ti abs ibib tot

L9   ANSWER 1 OF 38  WPIDS  COPYRIGHT 2004 THOMSON DERWENT on STN
TI   Composition useful for the treatment of e.g. diabetes, comprises particles
     comprised of a glucagon-like peptide-1 (GLP-1) compound complexed with a
     basic polypeptide.
AN   2003-312606 [30]   WPIDS
AB   WO 200298348 A UPAB: 20030513
```

NOVELTY - A composition (C1) comprises particles comprised of a glucagon-like peptide-1 (GLP-1) compound (a) complexed with a basic polypeptide (b), is new. The ratio of (a):(b) is 4:1 - 10:1. (b) is polylysine, polyarginine, polyornithine, protamine, putrescine, spermine, spermidine or histone (preferably polyarginine, protamine or polylysine, especially protamine).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for preparation of a composition involving preparing a **GLP-1 solution** comprised of (a), and basic polypeptide solution comprised of (b), adding an alcohol (c) to the GLP-1 and the basic polypeptide solution and mixing the **GLP-1 solution** with the basic polypeptide solution. The alcohol is ethanol, propanol, isopropanol and/or methanol (preferably ethanol).

ACTIVITY - Antidiabetic; Anorectic; Anti-inflammatory; Cardiant; Cerebroprotective.

MECHANISM OF ACTION - Insulin secretion stimulator.

USE - In the preparation of a medicament for the treatment of diabetes, hyperglycemia, obesity, irritable bowel syndrome, myocardial infarction and stroke in a mammal (claimed).

ADVANTAGE - The number mean diameter of the particles 1 - 5 (preferably 3 - 5, especially 1 - 3) micro m, or 4 micro m or 5 micro m. About 90% of the particles in (C1) are less than 12 (preferably less than 9, especially less than 7) micro m. The particles have a number diameter of 0.5 - 12 (preferably 1 - 5, especially 1 - 3) micro m. The particles of (C1) are small and possess aerodynamic properties such that the reach the deep lung by reducing problems associated bioavailability and adsorption variability. The particles have a sustained pharmacokinetic profile when delivered pulmonarily.

Dwg.0/0

ACCESSION NUMBER: 2003-312606 [30] WPIDS
DOC. NO. CPI: C2003-081793
TITLE: Composition useful for the treatment of e.g. diabetes, comprises particles comprised of a glucagon-like peptide-1 (GLP-1) compound complexed with a basic polypeptide.
DERWENT CLASS: A96 B04 D16
INVENTOR(S): DEFELIPPIS, M R; HAVEL, H A; MACE, K F; NG, K; SARIN, V K
PATENT ASSIGNEE(S): (ELIL) LILLY & CO ELI
COUNTRY COUNT: 100
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002098348	A2	20021212	(200330)*	EN	45

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002098348	A2	WO 2002-US15137	20020521

PRIORITY APPLN. INFO: US 2001-295282P 20010601

L9 ANSWER 2 OF 38 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid

and neutralizing the solution.

AN 2001-476192 [51] WPIDS

AB WO 200155213 A UPAB: 20010910

NOVELTY - Preparing a Glucagon-like peptide 1 (GLP-1) compound (I) from its insoluble form, comprising dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid (aa) racemization of the GLP-1 compound occurs; and isolating (I) from the neutralized solution, is new.

DETAILED DESCRIPTION - (I) is soluble in aqueous solution at pH 7.4 and the insoluble form is insoluble in aqueous solution at pH 7.4

USE - The method is used to prepare a soluble form of a GLP-1 compound (claimed), since the soluble form is physiologically active.

ADVANTAGE - Prior methods involve mixing and continuous movement through a pump. This leads to contact of the solution with air or hydrophobic surfaces and often results in the formation of the insoluble inactive form of GLP-1 compounds. The invented method provides a means of converting this by-product to soluble physiologically active GLP-1 compounds, resulting in high yields or more pure product.

Dwg.0/1

ACCESSION NUMBER: 2001-476192 [51] WPIDS

DOC. NO. CPI: C2001-142856

TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution.

DERWENT CLASS: B04 D16

INVENTOR(S): PROUTY JUNIOR, W F; RINELLA JUNIOR, J V; PROUTY, W F J; RINELLA, J V J; PROUTY, W F; RINELLA, J V

PATENT ASSIGNEE(S): (ELIL) LILLY & CO ELI; (PROU-I) PROUTY W F; (RINE-I) RINELLA J V

COUNTRY COUNT: 95

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001055213	A2	20010802	(200151)*	EN	49
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001032735	A	20010807	(200174)		
EP 1257577	A2	20021120	(200301)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
BR 2001007837	A	20030114	(200309)		
KR 2002073184	A	20020919	(200311)		
US 2003060412	A1	20030327	(200325)		
HU 2002004281	A2	20030428	(200337)		
JP 2003523366	W	20030805	(200353)		50
MX 2002007231	A1	20021201	(200377)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001055213	A2	WO 2001-US10	20010116
AU 2001032735	A	AU 2001-32735	20010116
EP 1257577	A2	EP 2001-904785	20010116
		WO 2001-US10	20010116
BR 2001007837	A	BR 2001-7837	20010116
		WO 2001-US10	20010116

KR 2002073184 A	KR 2002-709546	20020725
US 2003060412 A1	WO 2001-US10	20010116
	US 2002-169657	20020628
HU 2002004281 A2	WO 2001-US10	20010116
	HU 2002-4281	20010116
JP 2003523366 W	JP 2001-561060	20010116
	WO 2001-US10	20010116
MX 2002007231 A1	WO 2001-US10	20010116
	MX 2002-7231	20020725

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2001032735 A		Based on	WO 2001055213
EP 1257577	A2	Based on	WO 2001055213
BR 2001007837 A		Based on	WO 2001055213
HU 2002004281 A2		Based on	WO 2001055213
JP 2003523366 W		Based on	WO 2001055213
MX 2002007231 A1		Based on	WO 2001055213

PRIORITY APPLN. INFO: US 2000-224058P 20000809; US 2000-178438P 20000127; US 2002-169657 20020628

L9 ANSWER 3 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63303 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63303 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J.
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 4 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63302 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises

dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no
amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63302 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 5 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63301 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no
amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63301 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 6 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63300 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no

amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63300 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 7 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63299 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no
amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63299 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 8 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63298 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no
amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble

form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63298 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 9 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63297 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63297 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 10 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63296 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63296 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 11 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63295 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63295 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 12 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63294 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63294 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in

aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 13 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63293 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63293 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 14 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63292 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63292 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the

solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 15 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63291 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63291 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 16 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63290 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63290 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J

PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 17 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63289 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63289 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 18 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63288 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63288 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p

APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 19 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63287 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63287 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 20 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63286 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63286 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127

US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 21 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63285 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63285 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 22 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63284 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63284 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 23 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63283 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63283 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 24 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63282 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63282 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]

DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 25 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63281 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63281 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 26 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63280 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63280 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 27 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63279 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63279 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 28 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63278 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63278 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 29 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution

at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -

AN AAG63277 protein DGENE

AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63277 protein DGENE

TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -

INVENTOR: Prouty W F J; Rinella J V J

PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.

PATENT INFO: WO 2001055213 A2 20010802 49p

APPLICATION INFO: WO 2001-US10 20010116

PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-476192 [51]

DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 30 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -

AN AAG63276 protein DGENE

AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63276 protein DGENE

TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -

INVENTOR: Prouty W F J; Rinella J V J

PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.

PATENT INFO: WO 2001055213 A2 20010802 49p

APPLICATION INFO: WO 2001-US10 20010116

PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-476192 [51]

DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 31 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -

AN AAG63275 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63275 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 32 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63274 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.
ACCESSION NUMBER: AAG63274 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 33 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63273 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1

(GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63273 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: An insoluble glucagon-like peptide 1 (GLP-1) compound.

L9 ANSWER 34 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63272 protein DGENE
AB The present sequence represents a glucagon-like peptide 1 (GLP-1) analogue. The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63272 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: Glucagon-like peptide 1 (GLP-1) analogue Val8-GLP-1(7-37).

L9 ANSWER 35 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63271 protein DGENE
AB The present sequence represents a glucagon-like peptide 1 (GLP-1) analogue. The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound

that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63271 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: Amino acid sequence of glucagon-like peptide 1 (GLP-1) analogue.

L9 ANSWER 36 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63270 protein DGENE
AB The present sequence represents a glucagon-like peptide 1 (GLP-1) analogue. The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63270 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: Amino acid sequence of glucagon-like peptide 1 (GLP-1) analogue.

L9 ANSWER 37 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63269 protein DGENE
AB The present sequence represents a glucagon-like peptide 1 (GLP-1) analogue. The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound

that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63269 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: Amino acid sequence of glucagon-like peptide 1 (GLP-1) analogue.

L9 ANSWER 38 OF 38 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
AN AAG63268 protein DGENE
AB The present sequence represents an insoluble glucagon-like peptide 1 (GLP-1). The specification describes a method for preparing a GLP-1 compound that is soluble in aqueous form at pH 7.4 from a GLP-1 compound that is insoluble in aqueous form at pH 7.4. The method comprises dissolving the insoluble compound in aqueous base or acid; neutralizing the **GLP-1 solution** to a pH at which no amino acid racemisation of the GLP-1 compound occurs; and isolating GLP-1 from the neutralized solution. The method is used to prepare a soluble form of a GLP-1 compound. The soluble form of GLP-1 is physiologically active.

ACCESSION NUMBER: AAG63268 protein DGENE
TITLE: Preparing a Glucagon-like peptide 1 compound soluble in aqueous solution at pH 7.4, comprises dissolving the insoluble form in aqueous base or acid and neutralizing the solution -
INVENTOR: Prouty W F J; Rinella J V J
PATENT ASSIGNEE: (ELIL)LILLY & CO ELI.
PATENT INFO: WO 2001055213 A2 20010802 49p
APPLICATION INFO: WO 2001-US10 20010116
PRIORITY INFO: US 2000-178438 20000127
US 2000-224058 20000809
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-476192 [51]
DESCRIPTION: Amino acid sequence of an insoluble glucagon-like peptide 1 (GLP-1).